Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy

15 Sept 2022

Abstract excerpt

The development of immune checkpoint inhibitors is becoming a promising approach to fight cancers. Antibodies targeting immune checkpoint proteins such as CTLA-4 and PD-1 can reinvigorate endogenous antitumor T-cell responses and bring durable advantages to several malignancies. However, only a small subset of patients benefit from these checkpoint inhibitors. Identification of new immune checkpoints with the aim...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36189222
DOI: 10.3389/fimmu.2022.938470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapyPMID 36189222Read ↗

VISTA: A Promising Target for Cancer Immunotherapy?Semantic proximity Read ↗

VISTA expression and patient selection for immune-based anticancer therapySemantic proximity Read ↗

Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell ActivationSemantic proximity Read ↗

VISTA-mediated immune evasion in cancerSemantic proximity Read ↗

Immunoregulatory functions of VISTASemantic proximity Read ↗

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesSemantic proximity Read ↗

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapySemantic proximity Read ↗

Expression of the Immune Checkpoint Protein VISTA Is Differentially Regulated by the TGF-β1 – Smad3 Signaling Pathway in Rapidly Proliferating Human Cells and T LymphocytesSemantic proximity Read ↗

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlightsSemantic proximity Read ↗

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4Semantic proximity Read ↗

The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast CancerSemantic proximity Read ↗

Novel Immune Check-Point Regulators in Tolerance MaintenanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.